Related references
Note: Only part of the references are listed.Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
Russell Vang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer
Adam R. Blanden et al.
DRUG DISCOVERY TODAY (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Tan A. Ince et al.
NATURE COMMUNICATIONS (2015)
Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Ming-Tseh Lin et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
p53 as a target for the treatment of cancer
Michael J. Duffy et al.
CANCER TREATMENT REVIEWS (2014)
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis
Vanessa L. Beesley et al.
GYNECOLOGIC ONCOLOGY (2014)
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Guang-xia Chen et al.
ONCOTARGETS AND THERAPY (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
Bernard Leroy et al.
NUCLEIC ACIDS RESEARCH (2013)
Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing
Evgeny A. Moskalev et al.
VIRCHOWS ARCHIV (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
Casina W. S. Kan et al.
BMC CANCER (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
Paulina M. Wojnarowicz et al.
PLOS ONE (2012)
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Anna Yemelyanova et al.
MODERN PATHOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Expression signatures of TP53 mutations in serous ovarian cancers
Marcus Q. Bernardini et al.
BMC CANCER (2010)
p53 at a glance
Colleen A. Brady et al.
JOURNAL OF CELL SCIENCE (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas
Martin Koebel et al.
JOURNAL OF PATHOLOGY (2010)
GENOMICS In search of rare human variants
Rasmus Nielsen
NATURE (2010)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
The Origins and Evolution of the p53 Family of Genes
Vladimir A. Belyi et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
P. de Graeff et al.
BRITISH JOURNAL OF CANCER (2009)
Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas
Estrid V. S. Hogdall et al.
APMIS (2008)
Diagnostic markers for early detection of ovarian cancer
Irene Visintin et al.
CLINICAL CANCER RESEARCH (2008)
Serous tubal Intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention
Joseph W. Carlson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Shaping genetic alterations in human cancer: The p53 mutation paradigm
Thierry Soussi et al.
CANCER CELL (2007)
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Ronald Pak Cheung Wong et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Y. Lee et al.
JOURNAL OF PATHOLOGY (2007)
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
L Havrilesky et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Distinct subtypes of serous ovarian carcinoma identified by p53 determination
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2003)
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
JMJ Piek et al.
JOURNAL OF PATHOLOGY (2001)
Predicting deleterious amino acid substitutions
PC Ng et al.
GENOME RESEARCH (2001)
Share Paper
